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B.L.Y. Cheuk, A.C.W. Ting and S.W.K. Cheng*Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong, ChinaObjective. Serological studies have suggested that one of the risk factors for aneurysm development is C. pneumoniae
infection. The purpose of this study was to evaluate whether there is an association between the presence of C. pneumoniae
DNA in aneurysms and ruptured Abdominal Aortic Aneurysms.
Methods. Aortic walls were collected consecutively from 30 patients with intact AAA, 16 patients with ruptured AAA and
19 healthy organ donors (control). Purified DNAs from all aortas were analyzed for the presence ofC. pneumoniaeDNA in
parallel by polymerase chain reaction-enzyme immunoassay (PCR-EIA) and agarose gel electrophoresis. PCR-EIA has a
high sensitivity in detecting low DNA copy number in clinical atherosclerotic samples.
Results. C. pneumoniae DNA was detected more frequently in patients with aneurysms, particular with ruptured
aneurysms. The incidence of positive C. pneumoniae DNA was 73.3% in intact AAA and 10.5% in control aortas, with
the highest frequency in ruptured AAA (100%) (p!0.05).
Conclusion. Giving the high specificity and sensitivity of PCR-EIA, these findings support the association of C.
pneumoniae in the pathogenesis of aneurysm development, growth and rupture.Keywords: C. pneumoniae; Abdominal aortic aneurysm; Rupture; DNA; PCR-EIA.Introduction
Inflammation has been found to be an important event
in the development and progression of atherosclero-
sis.1 There is growing evidence that infections with
certain pathogens by initiating an inflammatory
response might contribute to this disease process.
Among some well-known infectious agents such as
Helicobacter pylori and cytomegatovirus, Chlamydia pneu-
moniae, an obligate intracellular bacterium, has been
implicated in the initiation of inflammatory response
that might contribute to atherosclerosis.2 C. pneumoniae
has also been suggested as an inflammatory agent
responsible for the destruction and weakening of the
aortic wall by the release of inflammatory mediators in
response to the atherosclerotic plaques.3 Cell biologi-
cal studies have revealed that Chlamydial heat shock
protein is able to stimulate cytokine anding author. Stephen W.K. Cheng, MS, FRCS, FACS,
ascular Surgery, Department of Surgery, University of
edical Centre, Queen Mary Hospital, Pokfulam Road,
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promote a pro-thrombotic endothelial and smooth
muscle cell phenotype.4 Therefore, it has been
suggested that C. pneumoniae might initiate athero-
sclerosis and subsequently contribute to aneurysm
development.
Seroepidemiologic studies have indicated an associ-
ation between chronic C. pneumoniae infection and
aneurysmal diseases. The organism has been demon-
strated in the serum of more than half of a cohort of
abdominal aortic aneurysms (AAAs).5,6 However,
Maass et al. strongly suggested that the contribution
of C. pneumoniae in initiating atherosclerosis requires
its presence in the aortas and serology is not useful to
identify patients with aortic C. pneumoniae infection.7
They found that serology had significantly less
sensitivity and positive predictive value for the
detection of chlamydial presence as compared with
PCR method.7 Several investigators have reported
pathogen-specific nonviable structures in atheroma-
tous tissues, although detection rates varied widely
with the techniques employed.8–10 Thus, detection of
aortic C. pneumoniae using a reliable method is
required to provide better infection information.Eur J Vasc Endovasc Surg 29, 150–155 (2005)
doi:10.1016/j.ejvs.2004.10.010, available online at http://www.sciencedirect.com onved.
Detection of CP by PCR-EIA in AAA 151An Italian research group was the first to report an
association with AAA and C. pneumoniae by detecting
C. pneumoniae DNA in the atherosclerotic plaques of
aortic aneurysms in 1996.11 In Finland, C. pneumoniae
DNAwas demonstrated in 6 of 6 aneurysm specimens
studied by PCR and 6 controls were all negative.12 The
detection of C. pneumoniae DNA in ruptured aneur-
ysms was only reported in Poland recently.13 How-
ever, molecular evidence supporting an association
between C. pneumoniae and AAA rupture in our
population is still required.
In 2002, a PCR-based enzyme immunoassay (PCR-
EIA) was introduced as a new and reliable tool in
molecular diagnosis. It is a hybridization capture assay
with high sensitivity, specificity, and a low rate of
contamination for DNA detection. In addition, the
results can be visualized faster and more sensitively
than agarose gel-based PCR assay. This technology has
recently been used for detecting C. pneumoniae in
intestinal mucosal biopsies,14 with immunohistochem-
ical and nested PCR methods failing to identify C.
pneumoniae antigen or DNA in the same tissues. Thus,
in the present study we aimed to collect both intact
and ruptured aortas from patients undergoing aneur-
ysmal repair and evaluate the prevalence of C.
pneumoniae DNA using this PCR-EIA technique with
the novel probe hybridized to a specific sequence of C.
pneumoniae gene.Materials and MethodsPatients
Between January 2002 and December 2003, 30 intact
AAA and 16 ruptured AAA specimens without
adherent thrombus were collected from consecutive
patients who underwent abdominal aortic aneurysmal
repair. For control purposes, 19 infrarenal aortic walls
were collected from age and sex matched organ
donors during transplantation organ procurement
for the present PCR-EIA study. All control specimens
were macroscopically free from atherosclerotic or
vascular diseases. Each specimen was divided into
two pieces. One half was snap-frozen in liquid
nitrogen within 10 min of collection, and stored in
liquid nitrogen until DNA extraction for PCR assay.
The remainder was fixed in 10% formalin for 12 h,
processed and embedded in paraffin wax for histology.
Written informed consent was obtained from all
participants, and the protocol was approved by the
Ethics Committee.Histological examination of normal and aneurysmal aortas
Paraffin embedded aortic specimen were cut into 3 mm
serial sections and then cleared, rehydrated by
sequential immersions in three changes of xylene,
followed by graded ethanol and distilled water and
then stained with hematoxylin (Merck, Darmstadt,
Germany). All sections were then dehydrated and
cleared by sequential immersion in gradient ethanol
and xylene.Tissue processing and DNA extraction
The DNA extraction from aortic walls was performed
according to the standard method with optimized
procedures.15 DNA concentration and purity were
estimated spectrophotometrically at optical density
(OD) 260/280 using an Eppendorf Biophotometer
(Hamburg, Germany).Polymerase chain reaction amplification of C. pneumoniae
DNA
The presence of C. pneumoniae DNA in the aortic walls
was determined by Light Diagnostics C. pneumoniae
OligoDetect@ Assay kit (Chemicon, Temecula, CA)
with a designed probe hybridized with the nucleotide
sequence of C. pneumoniae KDTA gene. It is a specific
and sensitive polymerase chain reaction-enzyme
immunoassay-based method for the qualitative detec-
tion of specific C. pneumoniae DNA. PCR were
performed in a final volume of 50 ml, which included
200 ng DNA extract, 1.25 units of AmpliTaq DNA
polymerase (Applied Biosystems, Foster City, CA),
0.2 mM dNTP, 1 mM MgCl2, and 0.3 mM primers mix.
The primers used in the present study were commer-
cially synthesized and provided in the assay kit
(Chemicon, Temecula, CA). A 40-cycle amplification
was performed consisting of denaturation at 94 8C for
60 s, annealing at 58 8C for 30 s, and extension at 72 8C
for 60 s. The denaturing temperature was maintained
for 5 min at 94 8C before the first cycle, and the
extension temperature was maintained for an
additional 8 min after the 40 cycles. Stringent precau-
tions against contamination were taken during the
specimen preparation and PCR amplification. The
efficiency of DNA extraction and the potential pre-
sence of PCR inhibitor(s) in the specimens were
monitored by the successful amplification of amplifi-
cation positive control from the assay kit.Eur J Vasc Endovasc Surg Vol 29, February 2005
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immunoassay
Amplified products were detected by the assay kit
with a 5 0 end biotin-labeled internal oligonucleotide
probe specific for C. pneumoniae (Chemicon, Temecula,
CA). The enzyme immunoassay detection was carried
out according to the manufacturer’s protocol. Briefly,
10 ml of PCR products and controls was added to the
designated well of the detection plate provided in the
assay kit. And then denatured by mixing with 5 ml
denaturation solution for 10 min at room temperature.
At the end of incubation, 85 ml of hybridization buffer
was added. Capture was allowed to proceed for
30 min at 37 8C in a water bath, and afterward the
wells were washed four times with 250 ml of washing
buffer at room temperature. This was followed by the
addition of 100 ml of ready to use Strep: HRP
Conjugated. The plates were incubated for 30 min at
37 8C with mixing, and the wells were washed four
times. A total of 100 ml (TMB/E) substrate solution was
added, and the plate was incubated for 10 min at 37 8C.
The OD of the color reaction was measured at 450 nm
with an automated ELISA reader. The run was
considered valid if all negative control values were
less than 0.15 OD units and the positive control values
were greater than 1.0 OD units. The background cut-
off value was calculated as the average of all negative-
control OD values plus 2 standard deviations (SD).
The positive cut-off value was calculated by adding
the average with 3 SD. A mean OD value from
duplicate tests was obtained from each sample. A
specimen was considered positive if the mean OD
value was greater than the background cut-off value.Detection of the amplification products electrophoretically
on ethidium bromide-stained agarose gels
An aliquot of 8 ml was withdrawn from each PCR
reaction tube, resolved in 2% agarose gels in 1! TBE
buffer, and visualized by ethidium bromide. The C.
pneumoniae amplification positive control and C.
pneumoniae DNA positive samples yielded a biotiny-
lated product 100 base pairs (bp) and 110 bp products
in length, respectively.Fig. 1. Aneurysmal artery revealed typical atherosclerosis
with cholesterol clefts, infiltration of lymphocytes and foamy
macrophages (stained with hematoxylin, !400
magnification).Statistical analysis
The C. pneumoniae DNA detection rate of each group
was compared by chi-square test. A p value of !0.05
was considered statistically significant.Eur J Vasc Endovasc Surg Vol 29, February 2005Results
Demographic data of AAA patients and healthy organ
donors are shown in Table 1. Of the 30 intact AAA
patients, 22 (73.3%) were males and with a mean age
69.5G10 years (range 49–77 years). Twelve (75%) of the
16 ruptured AAA patients were males and with a
mean age 72.1G7 years (range 50–79 years). The
control groups consisted of 14 men (73.7%) and with a
mean age 65.5G8 years (range 50–71 years). The mean
aneurysm diameter of the intact AAAs and ruptured
AAAs were 6.74G1 and 7.03G0.71 cm, respectively.
Age, gender, and size of aneurysms did not differ
among AAA patients groups. All aneurysmal aortas
revealed typical fibrosis of the intima with thickening,
atherosclerotic plaques with cholesterol clefts, foam
cells and infiltration of lymphocytes (Fig. 1).
The highest C. pneumoniae DNA positive rate was
found in ruptured AAA (100%) as compared with
73.3% of intact AAA and 10.5% in control aortas, p!
0.05. There was no significant relationship between
age, gender and size of aneurysm and C. pneumoniae
DNA detection.
The presence and mobility of PCR products was
also determined by the agarose gel electrophoresis.
Positive PCR-EIA results from any diseased aortas
(except one intact and two ruptured aneurysms) and
control aortas were reproduced in the gel electrophor-
esis with faint bands. The PCR amplification of C.
pneumoniae gene produced the expected 110 bp band
for aortas from ruptured AAA patients, indicating the
presence of C. pneumoniae DNA in ruptured aneur-
ysmal walls (Fig. 2). Representative bands for positive
Table 1. Demographic data of AAA patients and healthy organ donors (control)
Intact AAA patients
(nZ30)
Ruptured AAA patients
(nZ16)
Control (nZ19) p value
Age (years) 69.5G10 (49–77) 72.1G7 (50–79) 65.5G8.0 (50–71) NS
Sex (M:F) 2.8:1 3:1 2.8:1 NS
Diameter of aneurysm 6.74G1 cm 7.03G0.71 cm – NS
MeanGSD. *p is statistically significant as compared to control. NS is not significant.
Detection of CP by PCR-EIA in AAA 153C. pneumoniae PCR results in intact AAA and negative
PCR result for control aorta were also shown.Discussion
Atherosclerosis and its related disease, abdominal
aortic aneurysm (AAA), present a common vascular
condition with life-threatening implications. Rupture
of aneurysm is frequently lethal, and accounts for a
large percent of the morbidity and mortality.16
Differences in the conventional cardiovascular factors,
such as smoking, diabetes mellitus and hypercholes-
terolemia do not entirely account for the prevalence or
severity of AAA. Therefore, there is intense research
interest focused on seeking other atherogenic risk
factors. Increasing serological evidence supports an
association between C. pneumoniae and the pathogen-
esis of AAA.3,7 In the present study, we evaluated the
presence of C. pneumoniae DNA directly in aortic walls
obtained from intact AAA patients, ruptured AAA
patients and organ donors using a sensitive PCR-EIA
technique to amplify a portion of gene specific for C.
pneumoniae. Of the 19 control aortas, only two were
DNA positive suggesting a non-frequent presence of
the pathogen in the aortas of the organ donors. We
found that most AAA specimens housed C. pneumo-
niae DNA. The relatively high presence of this
bacterium is probably the result of persistent infection.
Metabolically inactive or killed organisms are rapidly
eliminated from humoral immune system, as opposedFig. 2. Representative gel photo of aneurysmal and control aorta
obtained from intact AAA patients and rAAA for aortas fromto actively growing C. pneumoniae.5 In addition,
extrinsic DNA is usually rapidly degraded by restric-
tion endonucleases, so the present finding can be
considered as an evidence for the presence of viable
pathogens in the diseased aortas.
C. pneumoniaeDNAwas specifically associated with
ruptured aneurysms in the present study. A previous
report showed that the annual expansion rate of small
aneurysms correlated positively with the serum levels
of IgA-antibodies against C. pneumoniae.17 Tambiah et
al. showed in an animal model that C. pneumoniae
antigen stimulated the dilatation of the abdominal
aorta.18 In addition, the presence of C. pneumoniae had
been found to contribute to plaque instability and lead
to fissuring.19 As rapidly expanding aneurysms are
more susceptible to rupture, the present finding imply
that C. pneumoniae infection may be a factor influen-
cing the expansion rate as well as eventual aneurysm
rupture.
Although the pathogenesis of abdominal aortic
aneurysm remains largely obscure, inflammation
mediated tissue proteolysis has been found to be
important in aneurysmal dilatation.20,21 The presence
of C. pneumoniae might worsen tissue damage by
initiating inflammation and exacerbating atherogen-
esis. Firstly, experimental aortic inflammation and
dilatation can be provoked by C. pneumoniae infec-
tion.18 Secondarily, infected vascular cells can produce
matrix-degrading metalloproteases, which are import-
ant in the degradation of connective tissue in AAA.22
In addition, C. pneumoniae is able to multiply ins for DNA against C. pneumoniae. (AAA illustrated for aortas
ruptured AAA patients).
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and aortic smooth muscle cells.25 Chronic C. pneumo-
niae infection has also been shown to induce a more
atherogenic lipid profile by elevating plasma trigly-
ceride and total cholesterol and reducing high-density
lipoprotein (HDL)-cholesterol.26 Hence it could be
assumed that C. pneumoniae may play a role in
initiating inflammatory response and triggering the
development of aortic aneurysms. How C. pneumoniae
gain access to the arteries is still unclear, but infected
monocytes/macrophages are thought to be potential
vectors for dissemination.9
The routine laboratory method for the detection of
C. pneumoniae infection is serological assay. However,
the value of serology has been questioned due to the
lack of specific antibodies in sera of patients from
whom the organism could be isolated.27 In addition,
serological diagnosis is hampered by the slow anti-
body response to C. pneumoniae. Ericson found that the
degree of immune response was not a predictor of the
extent of infection, however, intra-arterial detection of
C. pneumoniae was related to the severity of the
cardiovascular diseases.28
In addition to seroepidemiologic studies, a possible
etiologic link has also been investigated through the
demonstration of an organism in atherosclerotic
lesions using isolation in tissue culture, immunohis-
tochemistry (IHC) and polymerase chain reaction
(PCR).29 However, C. pneumoniae is difficult to recover
from clinical samples. Generally, immunological
detection finds more evidence for C. pneumoniae than
PCR.30 These uncertainties make it difficult to estimate
the prevalence of C. pneumoniae in blood vessels,
particularly as specimens positive accordingly to one
technique were not necessarily positive by another.31
PCR technology is particularly good in this aspect.
Nested PCR with 16s rRNA-based primers have been
reported to be more sensitive than single-step PCR
assay, but the high risk of carry over contamination is
still a problem of nested PCR. Several groups have
failed to identify any specific C. pneumoniae DNA in
tissues from AAA patients using nested PCR.32–34 The
poor visualization of agarose gel after nested PCR is
also another serious disadvantage for low DNA copy
numbers in clinical samples. To facilitate the detection
of C. pneumoniae DNA by PCR, a sensitive enzyme
immunoassay (EIA) for analysis of PCR products was
used in this study. This EIA assay was specific for C.
pneumoniae because it does not show any cross
amplifications for DNA samples from the other three
Chlamydia species. This assay is also 10 times more
sensitive than normal fluorescent staining of PCR
product on agarose gels. Our study clearly demon-
strated that EIA is more sensitive than gelEur J Vasc Endovasc Surg Vol 29, February 2005electrophoresis, because EIA can detect C. pneumoniae
DNA in agarose gel negative aortas, despite the fact
that both expression techniques were amplifying the
same DNA fragment.
Since C. pneumoniae are susceptible to antimicrobial
therapy, its potential role in the development of
atherosclerosis and aortic aneurysms might result in
a radical change in current clinical practice. The
initiation of the atherosclerotic lesion as well as the
promotion of existing vascular damage by C. pneumo-
niae infection is certainly conceivable. Further exper-
imental work is required for investigating its etiologic
role in vascular pathology.
Presently, PCR combined with EIA hold promise as
useful molecular tools for the detection of C. pneumo-
niae DNA in aneurysmal samples. Our results add to
the controversy regarding the role of C. pneumoniae in
AAA development.21,32 Our findings suggest that
chronic chlamydial infection could accelerate the rate
of aneurysmal growth and lead to rupture. Quantitat-
ive and time course analysis of C. pneumoniae may be
needed to support this claim. As antibiotics treatment
against C. pneumoniae is available, further studies are
needed to determine the significance of aortic infection
in aneurysm development and expansion.References
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